| Document |
Document Title |
|
WO/2024/077148A1 |
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the plasminogen (PLG) gene, as well as methods of inhibiting expression of PLG, and methods of treating subjects that would benefit from reduction i...
|
|
WO/2024/074143A1 |
Provided is an expression construct, vectors, viral particles, or compositions. The expression construct comprises a transcription regulatory element operably linked to a polynucleotide sequence of interest, wherein the expression constr...
|
|
WO/2024/074825A1 |
The invention concerns a modified adenoviral vector of serotype Ad5 comprising a suicide transgene; a pharmaceutical composition comprising same; a combination therapeutic comprising same, the use of said adenoviral vector or pharmaceuti...
|
|
WO/2024/077262A2 |
Disclosed are compositions and methods for reducing expression of ELAVL2. It has been determined that GGGGCC (G4C2) repeat expansion in the first intron of C9ORF72 is the most commonly known genetic cause of amyotrophic lateral sclerosis...
|
|
WO/2024/076507A1 |
Methods for improving parthenogenesis efficiency by DWT1 and BABY BOOM transcription factors in plants are provided. A rice embryo trigger transcription factor BABY BOOM1 can initiate embryogenesis when expressed in the unfertilized egg ...
|
|
WO/2024/077071A2 |
Artificial antigen presenting cells (aAPC) including a major histocompatibility class II (MHC II) molecule and methods of their use for identifying, isolating, or detecting one or more antigen-specific T cells, and treating a disease, di...
|
|
WO/2024/076530A1 |
This document provides methods and materials for treating a mammal (e.g., a human) having a disease or disorder condition associated with an elevated level of a plurality of senescence-associated secretory phenotype (SASP) polypeptides (...
|
|
WO/2024/076473A1 |
The present disclosure relates to compositions of matter and assay methods used to screen for molecular dimerization events using a two-ribonucleoprotein complex signal boost assay. The compositions and methods provide a readout upon det...
|
|
WO/2024/076525A1 |
The present invention is directed to an agricultural mixture comprising 1-amino-1-cyclopropanecarboxylic acid, a hydrate thereof, a polymorph thereof or a salt thereof and methyl jasmonate. The present invention is further directed to a ...
|
|
WO/2024/074727A1 |
The invention relates to an immune cell engineered to express a chimeric antigen receptor (CAR) which specifically binds Fibroblast Activation Protein (FAP) for use in the treatment of skeletal muscle fibrosis in muscular dystrophies.
|
|
WO/2024/067780A1 |
Provided is a codon optimization method for reducing the immunogenicity of exogenous nucleic acids. The method comprises the following steps: a) obtaining an initial nucleic acid sequence population set, wherein the initial nucleic acid ...
|
|
WO/2024/073669A1 |
Provided herein are methods of treating neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR) in a subject in need thereof comprising administering an anti-hVEGF treatment and a steroid treatment; wherein the ...
|
|
WO/2024/065649A1 |
Provided is a method for efficiently loading DNA into an exosome, wherein the exosome is derived from mammalian cells or milk. A highly compressed DNA-polycationic compression agent complex is formed by combining a polycationic compressi...
|
|
WO/2024/066822A1 |
The present invention provides a method for producing γ-butyrolactone or 1,4-butanediol by fermentation. By means of a synthetic biology technique, Corynebacterium glutamicum is taken as a chassis, and an exogenous glutamate decarboxyla...
|
|
WO/2024/071923A1 |
According to an aspect of the technology disclosed in the present application, the present invention relates to a cell line in which exosomes loaded with FAF1 protein are stably expressed, and relates to: a cell line, which can produce, ...
|
|
WO/2024/067888A1 |
Provided is a varicella zoster vaccine. Specifically, the vaccine comprises an immune composition, and the immune composition comprises an antigen component and a granulin component. The granulin component comprises a nanogranulin protei...
|
|
WO/2024/071960A1 |
The present invention relates to: a peptide tag based on a dispersed His-tag and charged and hydrophobic amino acids forming a self-assembly; a fusion protein in which the tag and a target protein are fused; and a target protein purifica...
|
|
WO/2024/068760A1 |
This invention relates to methods of making immunoresponsive cells, immunoresponsive cells thereof, pharmaceutical compositions, kits, uses thereof and methods of treatment. In particular, there is provided a method of making an immunore...
|
|
WO/2024/071527A1 |
The purpose of the present invention is to provide a tag for increasing the expression of a membrane protein and use thereof. Specifically, the tag according to the present invention significantly increases the expression of various type...
|
|
WO/2024/072006A1 |
The present invention relates to a method for generating a total mRNA-based random sgRNA library through an enzymatic reaction. The method according to the present invention may generate an sgRNA library that may target the entire genome...
|
|
WO/2024/069180A2 |
Provided herein are multivalent protein scaffolds useful as therapeutics, and useful in identifying new therapeutic compounds. The invention also relates to multi-domain polypeptide constructs having multiple binding domains and a struct...
|
|
WO/2024/068990A1 |
The present invention relates to a chimeric helper nucleic acid molecule comprising helper elements from three distinct helper viruses, helper-free virus methods and systems for producing infectious recombinant adeno-associated virus (rA...
|
|
WO/2024/071039A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2024/073755A2 |
Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids ("BIAs") such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocod...
|
|
WO/2024/068683A1 |
A stationary phase for use in affinity chromatography for recovering adeno-associated virus (AAV) vectors (3) from a solution. The stationary phase comprises a porous polymer matrix (1) having a mean flow pore size of 0.1-2.0 µm, wherei...
|
|
WO/2024/065376A1 |
Disclosed in the present invention is the use of a differentially methylated region of callipyge gene in meat trait breeding. Disclosed in the present invention is a differentially methylated region from an imprinted region Dlk1-Mirg of ...
|
|
WO/2024/066026A1 |
Provided is a chimeric antigen receptor targeting IL13Rα2, comprising: (1) an optimized anti-IL13Rα2 scFv sequence; (2) an optimized hinge region/spacer region; (3) a transmembrane region (TM); (4) a CD28 costimulatory domain and a 4-1...
|
|
WO/2024/065959A1 |
Provided are a rape green revolution gene bgr and a use thereof. The gene bgr can significantly reduce the height of rape plants, achieve thick and strong stems, lodging resistance, a reduced branching angle, and a compact plant type, an...
|
|
WO/2024/068898A1 |
The present invention provides pre-mRNA trans-splicing molecules (RTMs) that are useful for correcting mutations in the OPA1 gene. Also provided are methods of using the RTMs as gene therapy (e.g., ex vivo and in vivo gene therapy) for t...
|
|
WO/2024/072890A1 |
Methods and materials involved in reducing the level of a long noncoding RNA of fat mass and obesity-associated protein (FTO-IT1) in a cell are provided herein.
|
|
WO/2024/071397A1 |
The present invention provides an IL13RA2-targeting herpes simplex virus in which an anti-IL13RA2 antibody or an antigen-binding fragment thereof is presented on the viral surface. Also provided is an anti-IL13RA2 antibody or an antigen-...
|
|
WO/2024/067344A1 |
The present invention relates to an antibody or an antigen-binding fragment for specifically recognizing LIGHT, a preparation method therefor, and use thereof.
|
|
WO/2024/072998A1 |
The disclosure relates to adoptive cell therapy compositions including a population of isolated immune cells that are obtained from a donor subject. The immune cells can be modified to suppress Bruton's tyrosine kinase (BTK), interleukin...
|
|
WO/2024/071956A1 |
The present invention relates to a fusion polypeptide and a method for purifying a target protein by using same, the polypeptide having any one from among a His tag, a HAT tag and an HQ tag, and an α-helix peptide tag of which the major...
|
|
WO/2024/072897A1 |
Provided herein are methods, compositions, reaction mixtures, kits and systems for measuring protease activities, detecting protein-protein interactions, and identifying signaling molecules that induce protein-protein interactions. In pa...
|
|
WO/2024/065297A1 |
Embodiments of the present invention provide a chimeric antigen receptor with a light chain variable region having a sequence set forth in SEQ ID NO: 1 and a heavy chain variable region having a sequence set forth in SEQ ID NO: 2. The ch...
|
|
WO/2024/073715A2 |
Described herein are gene-targeted therapies and compositions that can include a vessel-specific viral vector, preferably in combination with a HDAC9-derived promoter to transduce SMC and deliver a base editor that corrects mutant allele...
|
|
WO/2024/067759A1 |
The present invention relates to a novel humanized anti-human CLDN18.2 antibody and an antigen-binding fragment thereof. The present invention also relates to a preparation method for the antibody. The present invention further relates t...
|
|
WO/2024/073689A1 |
Synthetic polynucleotide libraries may include a plurality of polynucleotides. The polynucleotides may comprise DNA and may be configured to hybridize with one or more regions of target nucleic acids. The target nucleic acids may compris...
|
|
WO/2024/066819A1 |
Disclosed is a method for producing 3-hydroxypropionic acid and acrylic acid by means of fermentation. The present invention provides a recombinant Corynebacterium glutamicum. The aldehyde dehydrogenase gene ald of the microorganism is u...
|
|
WO/2024/072882A1 |
Provided herein are vectors including a polynucleotide encoding an α9L9'T protein, pharmaceutical compositions including the vector including a polynucleotide encoding an α9L9'T protein, and methods of use thereof. The methods of use i...
|
|
WO/2024/067821A1 |
Provided is a modified cell, wherein the modified cell is formed by binding a complex protein to a cell surface marker molecule of the modified cell. The complex protein comprises a part specifically binding to the cell surface marker mo...
|
|
WO/2024/065651A1 |
The present invention relates to a method for loading a dimer CD24 into an HEK293 cell exosome with ADAM10 gene knocked out. By means of loading a dimer CD24 and/or ApoE protein into an HEK293 cell exosome with ADAM10 gene knocked out, t...
|
|
WO/2024/072775A1 |
The present disclosure provides devices, systems, kits, and related methods for isolating DNA from a sample (e.g., plasma) using RNA-guided DNA binding proteins (e.g., Cas proteins). Particularly, the disclosure provides devices, systems...
|
|
WO/2024/073726A2 |
The present disclosure relates to engineered cells expressing heterologous MUC1, MUC1-C or MUC1-C cytoplasmic domain for generating induced pluripotent stem cells that are autologous to a subject.
|
|
WO/2024/071279A1 |
Provided is a super-high-molecular gamma-polyglutamic acid having an average molecular weight of at least 20 million. Also provided is a Bacillus genus bacterium variant strain that can produce said super-high-molecular γ-PGA. Further p...
|
|
WO/2024/067747A1 |
The present invention provides a 5'-UTR sequence capable of improving the translation efficiency of a protein coding region, and a use thereof. The 5'-UTR sequence of the present invention can improve the translation efficiency of the pr...
|
|
WO/2024/071924A1 |
In one embodiment of the present invention, the present invention relates to an exosome and uses thereof, the exosome comprising a protein that induces cell death and a polypeptide that increases the half-life of an exosome. The exosome ...
|
|
WO/2024/067861A1 |
Provided herein are therapeutic nucleic acid molecules for managing, preventing and/or treating infectious diseases caused by coronavirus. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, com...
|
|
WO/2024/067644A1 |
A method for cell-free preparation of an mRNA transcription template, the method comprising the following steps: 1) in the presence of at least one type of primer and while promoting the amplification of a DNA template, causing contact o...
|
